Summary
Boston Scientific Corporation (BSX) filed an 8-K on February 3, 2021, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2020. The press release, furnished as Exhibit 99.1, provides key details on the company's operational and financial performance during this period. Investors should review this press release for a comprehensive understanding of the reported results, which may include revenue, earnings, and other financial metrics that impact the company's valuation and future outlook. This filing serves as the official notification of these results, and while not deemed "filed" for certain legal purposes, it represents crucial information for market participants. Investors interested in BSX's performance in late 2020 and its financial condition at year-end should consult the attached press release for specific figures and management commentary.
Key Highlights
- 1Boston Scientific announced its Q4 and full-year 2020 financial results on February 3, 2021.
- 2The results were disclosed via a press release furnished as Exhibit 99.1 with the 8-K filing.
- 3The filing is primarily informational, providing investors with access to the earnings release.
- 4Item 2.02 of the 8-K covers Results of Operations and Financial Condition.
- 5Item 9.01 details the exhibits, including the press release (Exhibit 99.1) and the Cover Page Interactive Data File (Exhibit 104).
- 6The information is not deemed "filed" for certain SEC purposes, but is crucial for investors to review.
- 7Investors are directed to the press release for specific financial performance details for the period ending December 31, 2020.